Melanoma Dispatch
2.7K views | +0 today
Follow
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO

Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO | Melanoma Dispatch | Scoop.it

"Amgen today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma. The findings were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago."


Editor's note: This article describes promising results for a melanoma treatment called talimogene laherparepvec (T-VEC), an immunotherapy that boosts a patient's own immune system to fight cancer. Previous testing of the drug has found mixed results.

Cancer Commons's insight:

MarketWatch  |  Jun 2, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Anti-Melanoma Vaccine May Extend Life

Anti-Melanoma Vaccine May Extend Life | Melanoma Dispatch | Scoop.it

Results of a late-stage clinical trial suggest that an experimental immunotherapy may boost survival in people with melanoma. Called talimogene laherparepvec (T-VEC), the vaccine includes a gene called granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system. The researchers found that people injected with T-VEC lived an average of 4 months longer than those treated with GM-CSF on its own (23 vs 19 mo). In addition, T-VEC made more tumors disappear or shrink by at least half.

Cancer Commons's insight:

Amgen│Nov 18, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Engineered Virus Shrinks Melanoma Tumors in Phase III Trial

Engineered Virus Shrinks Melanoma Tumors in Phase III Trial | Melanoma Dispatch | Scoop.it

Researchers report that a modified cold sore virus may help deliver longer lasting shrinkage of melanoma tumors. Called talimogene laherparepvec (T-VEC), the engineered virus kills cancer cells directly and boosts the immune response against them by tagging their surfaces with a protein called granulocyte macrophage colony-stimulating factor (GM-CSF). T-VEC outperformed GM-CSF (administered directly) in a phase III trial of 436 people with melanomas that had spread—tumors shrank more often (26% vs 6%) and were more likely to stay shrunk for at least 6 months (16% vs 2%). The researchers caution that while promising, T-VEC is unlikely to be a stand-alone treatment and suggest that this virus might ultimately be combined with another immunotherapy such as ipilimumab.

Cancer Commons's insight:

ASCO Daily News│Jun 3, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

T-VEC Keeps Shrinking Melanomas

An experimental vaccine that is injected into melanomas can shrink them for an average of 8 months, according to findings presented at the American Society of Clinical Oncology's 2013 meeting. Called talimogene laherparepvec (T-VEC), this immunotherapy consists of a virus engineered to carry human genes for granulocyte macrophage colony-stimulating growth factor (GM-CSF). Once inside a tumor, T-VEC kills tumor cells both by bursting them and by boosting the immune response against them. In a phase III clinical trial, melanomas shrank in 16% of those injected with T-VEC (48 out of 295) compared to just 2% of those treated directly with GM-CSF (30 out of 141). Moreover, melanomas disappeared completely in more than 10% of those treated with T-VEC. Doctors caution that because T-VEC is injected into melanomas, this treatment is only practical for people with accessible tumors.

Cancer Commons's insight:

Clinical Oncology News  |  Dec  2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Combination Immunotherapy Boosts Survival in Melanoma Patients

Combination Immunotherapy Boosts Survival in Melanoma Patients | Melanoma Dispatch | Scoop.it

People with melanoma may live longer when treated with two drugs that boost the immune system, suggest early results from a clinical trial. The drugs are ipilimumab, which is FDA approved, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which is experimental. In a phase II trial of 245 people with melanoma, more were alive at 1 year when treated with both drugs than when treated with ipilimumab alone (69% vs 53%). The combination treatment also helped alleviate the severe toxic side effects of ipilimumab, which dropped from 58% to 45%. These findings were among several advances in immunotherapy treatments for melanoma presented at the American Society of Clinical Oncology's 2013 meeting.

Cancer Commons's insight:

The Oncology Report│Jun 2, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Injections that Boost the Immune System Help Shrink Melanomas

Injections that Boost the Immune System Help Shrink Melanomas | Melanoma Dispatch | Scoop.it

A phase III trial suggests that a virus-based treatment could help control melanomas that have spread, according to the pharmaceutical firm Amgen. The treatment, called talimogene laherparepvec, or TVEC, involves injecting tumors with a modified cold sore virus. The modifications make the virus grow in cancer cells, but not in normal cells, and make the cancer cells produce a protein called GM-CSF that stimulates the immune system. More than 250 people in the trial received TVEC injections every two weeks and tumors shrank in about 40 (16%) of those who were treated.

Cancer Commons's insight:

The New York Times │ Mar 19 2013

more...
No comment yet.